INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

Rhea-AI Summary

INmune Bio (NASDAQ: INMB) reported new Phase 2 neuroimaging analyses from the MINDFuL trial of XPro1595 in early Alzheimer’s disease patients with elevated neuroinflammation (ADi). Presented at CTAD Dec 1-4, 2025, the PerpPD+ grey-matter MRI analysis showed a trend toward slowed progression of cortical disarray in XPro1595-treated, dose-compliant ADi participants at 24 weeks.

The company says these imaging signals align with directional improvements in biological, cognitive, and neuropsychiatric endpoints and that additional MRI analyses are expected in 2026.

News Market Reaction – INMB

-10.06%

13 alerts

-10.06% News Effect

-17.7% Trough in 2 hr 53 min

-$5M Valuation Impact

$46M Market Cap

0.9x Rel. Volume

On the day this news was published, INMB declined 10.06%, reflecting a significant negative market reaction. Argus tracked a trough of -17.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $46M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Treatment duration: 24 weeks CTAD conference dates: December 1–4, 2025 CTAD edition: 18th +2 more

5 metrics

Treatment duration 24 weeks Change from baseline in PerpPD+ at 24 weeks in MINDFuL trial

CTAD conference dates December 1–4, 2025 18th Clinical Trials on Alzheimer’s Disease conference timing

CTAD edition 18th 18th Clinical Trials on Alzheimer’s Disease conference

Trial phase Phase 2 MINDFuL trial of XPro1595 in early Alzheimer’s disease

Additional data timing 2026 Further MRI analyses from MINDFuL expected

Market Reality Check

Price: $1.31 Vol: Volume 498,675 is roughly...

normal vol

$1.31 Last Close

Volume Volume 498,675 is roughly in line with the 508,941 share 20-day average (relative volume 0.98). normal

Technical Shares at $2.14 are trading below the 200-day moving average around $4.41, after a large drawdown from the $11.64 52-week high.

Peers on Argus

Peer moves are mixed: JUNS up 5.36% and PDSB up 1.00%, while GNTA, PYPD, and VTV...

1 Down

Peer moves are mixed: JUNS up 5.36% and PDSB up 1.00%, while GNTA, PYPD, and VTVT are down between about 1–5%. With only VTVT flagged in momentum scanners and no peer news today, the reaction to this Alzheimer’s imaging update appears stock-specific rather than a coordinated biotech move.

Historical Context

5 past events · Latest: Dec 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	Scientific publication	Positive	+1.3%	Peer-reviewed overview supports therapeutic potential of CORDStrom platform.
Dec 01	Alzheimer’s imaging data	Positive	-10.1%	Phase 2 MINDFuL PerpPD+ imaging shows trend to slowed cortical disarray.
Nov 18	Conference preview	Neutral	+2.7%	Announcement of two CTAD posters including MINDFuL results and EMACC work.
Oct 30	Q3 earnings update	Neutral	-5.0%	Q3 loss, cash balance, and progress across CORDStrom, XPro1595, and INKmune.
Oct 23	Earnings call notice	Neutral	+0.6%	Scheduling of Q3 2025 results call and webcast details.

Pattern Detected

Clinical and scientific updates often show volatile and sometimes contrarian reactions, with several positive Alzheimer’s and trial milestones followed by negative price moves, while smaller corporate or conference updates have tended to see modest, more aligned reactions.

Recent Company History

Over the last few months, INmune Bio has alternated between clinical milestones and corporate updates. On Feb 12, it advanced the INKmune™ prostate cancer program into Phase II with a positive price reaction. Through Apr 1 and Jun 30, MINDFuL trial disclosures in Alzheimer’s disease highlighted promising high‑inflammation subgroups but were met with selling pressure. The current CTAD grey‑matter imaging data on Dec 1 fits this Alzheimer’s subgroup narrative, while the Q3 Oct 30 update and early December stromal‑therapy publication show more muted stock responses.

Market Pulse Summary

The stock dropped -10.1% in the session following this news. A negative reaction despite biologicall...

Analysis

The stock dropped -10.1% in the session following this news. A negative reaction despite biologically supportive imaging could fit prior patterns, where Alzheimer’s trial updates occasionally saw selling even with positive ADi subgroup trends. Historical clinical catalysts averaged moves of 18.05%, underscoring volatility risk. With shares already far below the 52-week high and under the 200-day MA, traders have previously reassessed risk around complex data readouts, leading to sharp but not always lasting drawdowns.

Key Terms

mri, biomarkers, soluble tnf, innate immune system, +2 more

6 terms

mri medical

"Using PerpPD+, a next-generation MRI imaging analysis that quantifies the diffusion"

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

biomarkers medical

"patients with early Alzheimer’s disease (AD) and elevated inflammatory biomarkers."

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

soluble tnf medical

"supporting XPro1595’s mechanism of selectively neutralizing soluble TNF (sTNF)."

Soluble TNF is the circulating form of tumor necrosis factor, a small signaling protein the immune system uses to call cells to action during inflammation. It matters to investors because levels of soluble TNF can serve as a measurable marker of disease activity and because many drugs aim to block it; changes in test results, trial outcomes or regulatory status for TNF-targeting therapies can directly affect a company’s value.

innate immune system medical

"the powerful role the innate immune system plays in Alzheimer’s disease pathology."

The innate immune system is the body's first line of defense made up of cells and proteins that respond quickly and broadly to infections or injury, like a neighborhood security team that reacts to any obvious threat. For investors, it matters because therapies or diagnostics that target or trigger this system can affect treatment effectiveness, safety profiles, clinical trial results and regulatory decisions, all of which influence a biotech or healthcare company's value.

cortical disarray medical

"cortical disarray measurement (CDM) was one of the secondary outcome measures"

Cortical disarray is a microscopic finding where the normally orderly layers of cells in the outer (cortical) part of an organ become jumbled or irregular, like bricks in a wall that have been shifted out of line. Pathologists see it on tissue samples and it often signals abnormal development, injury, inflammation, or a tumor. For investors, its presence in clinical or biopsy reports can affect drug or device safety assessments, trial outcomes, regulatory review, and potential liability.

randomized, double-blind, placebo-controlled medical

"Phase 2 randomized, double-blind, placebo-controlled study in patients with early"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

AI-generated analysis. Not financial advice.

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), being held on December 1-4, 2025 in San Diego, CA.

The new analyses add to the growing body of clinical, biomarker, and imaging evidence supporting XPro1595’s mechanism of selectively neutralizing soluble TNF (sTNF). The data further validate the Company’s strategy of targeting inflammation-driven AD, a large, underserved subset representing a significant unmet need and potential commercial opportunity.

New Grey Matter Signals Strengthen Biological Rationale for XPro1595

Using PerpPD+, a next-generation MRI imaging analysis that quantifies the diffusion components of water molecules that are perpendicular to the cortical gray matter’s minicolumns in the brain (PerpDP+, from Oxford Brain Diagnostics), investigators observed a trend towards slowed neurodegeneration progression in patients receiving XPro1595. These analyses focused on participants with early AD and high inflammatory burden (ADi), including the dose-compliant subgroup.

The PerpPD+ findings suggest attenuated increases in cortical disarray, an imaging hallmark associated with neurodegeneration. These results reinforce previously reported directional improvements across biological, cognitive, and neuropsychiatric endpoints and align with XPro1595’s mechanism of reducing innate immune dysfunction.

“These PerpDP+ data represent one of the clearest signals yet that selectively neutralizing soluble TNF can interrupt the neurodegenerative cascade at its microstructural root in AD driven by inflammation,” said Dr. CJ Barnum, Head of Neuroscience at INmune Bio. “We are excited to analyze the remaining imaging data and to report on this at subsequent meetings and in publications.”

Dr. Steven Chance, CEO of Oxford Brain Diagnostics added:

“XPro1595 is one of the pioneering interventions to examine the powerful role the innate immune system plays in Alzheimer’s disease pathology. Quantitative and precise biomarkers like cortical disarray measurement (CDM) was one of the secondary outcome measures in INmune Bio’s Phase 2 Alzheimer’s study. In the dose compliant participants, CDM showed a trend for reduced cortical disarray, indicating lower neurodegeneration."

Key Highlights

• The poster presentation of XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial outlines the first neuroimaging results of the Company’s Phase 2 randomized, double-blind, placebo-controlled study in patients with early Alzheimer’s disease (AD) and elevated inflammatory biomarkers receiving either XPro1595 or placebo. Results in the change from baseline at 24 weeks in PerpPD+, a grey matter imaging analysis developed by Oxford Brain Diagnostics, were analyzed in participants with early AD and a high inflammatory burden (ADi) and in dose-compliant ADi.
• The data show XPro1595 slowed disease progression as observed by a trend in an attenuated increase in PerpPD+, which indicated microscopic disruption of disarray in cortical structure. This reduction may indicate a slowing of neurodegeneration in the target population. In addition, these neuroimaging results are supportive of the previously reported directional effects on biological, cognitive and neuropsychiatric endpoints.

Additional Imaging Analyses Expected in 2026

INmune Bio confirmed that additional MRI analyses from the MINDFuL trial are ongoing and will be presented when available. These forthcoming data are expected to provide a broader picture of XPro1595’s tissue-level impact on both gray- and white-matter integrity in ADi.  

The Company believes totality of data generated to date, including the neuroimaging findings, position XPro1595 as a promising first-in-class disease-modifying therapy for the large subset of Alzheimer’s patients with elevated neuroinflammation. This population has limited treatment options, and no currently approved therapy is designed to target innate immune dysfunction.

About XPro™

XPro™ (Xpro1595, pegipanermin) is a next-generation inhibitor of soluble tumor necrosis factor (sTNF) that preserves trans-membrane TNF (tmTNF) and TNF-receptor signaling. By selective neutralizing sTNF, XPro™ aims to restore healthy innate immune function without the immunosuppressive liabilities associated with traditional TNF inhibitors. XPro™ is currently in clinical development for neurological diseases driven by chronic inflammation.

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune dysfunction to fight disease. The Company’s pipeline include:

• CORDStrom™, an allogeneic mesenchymal stromal cell platform that recently completed a randomized, blinded study in recessive dystrophic epidermolysis bullosa.
• DN-TNF Platform (XPro™/XPro1595), for neuroinflammatory and neurodegenerative conditions.
• INKMune™, designed to prime natural killer cells (NK) to eliminate minimal residual disease in cancer.
  
  

For more information, please visit www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com

Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com

FAQ

What did INMB announce at CTAD 2025 about XPro1595 imaging results?

INMB reported Phase 2 PerpPD+ MRI analyses showing a trend toward attenuated cortical disarray progression in dose-compliant ADi participants at 24 weeks.

Which patient subgroup showed the PerpPD+ imaging trend in the MINDFuL trial (INMB)?

The PerpPD+ trend was observed in participants with early Alzheimer’s disease and a high inflammatory burden (ADi), including the dose-compliant subgroup.

What is PerpPD+ and how was it used in INMB’s MINDFuL study?

PerpPD+ is a next-generation MRI analysis quantifying diffusion perpendicular to cortical minicolumns; it was used to assess grey-matter microstructural disarray at 24 weeks.

Does INMB claim XPro1595 is disease modifying based on these CTAD 2025 results?

The company said the imaging and prior directional biological and clinical signals position XPro1595 as a promising first-in-class therapy for inflammation-driven AD, but presented the imaging result as a trend.

When will INMB provide more imaging data from the MINDFuL trial?

INMB confirmed additional MRI analyses are ongoing and expected to be presented when available in 2026.

How do the PerpPD+ findings relate to XPro1595’s mechanism for INMB?

INMB says the PerpPD+ trend is consistent with XPro1595’s selective neutralization of soluble TNF and its intended effect on innate immune-driven neurodegeneration.